BofA Securities raised the price target for the Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) stock to “a Buy”. The rating was released on July 20, 2023, according to finviz.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) raised 0.36% to close Friday’s market session at $5.53, higher as compared to yesterday’s close. The stock price fluctuated between $5.27 and $5.65 throughout the trading session with the volume trading being 1026133 shares, which represented a significant variation when compared to the three months average volume of 1.11 million shares. The firm’s stock price fluctuated -1.51% within the last five trades and -18.56% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 37.91% in the last 6 months and -1.43% was subtracted to its value over the previous 3 months. ABOS stock is trading at a margin of -8.60%, -15.74% and 1.24% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ABOS deals in the Healthcare domain. The stock is trading -51.10 percent below its 52-week high and 57.10 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -45.7. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Acumen Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $318.92 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 1.34, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 7.83 percent of Acumen Pharmaceuticals Inc. shares are owned by insiders, and 77.20 percent are held by financial institutions. Ives Jeffrey L., the Director at Acumen Pharmaceuticals Inc. (ABOS) has sold 41,949 shares of firm on Aug 17 at a price of $6.49 against the total amount of $0.27 million. In another inside trade, RA CAPITAL MANAGEMENT, L.P., Director of Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) bought 5,161,290 shares of the firm on Jul 21 for a total worth of $40.0 million at a price of $7.75.